Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This study was designed to explore the clinical efficacy of Anlotinib combined with Anti-PD-1 antibody AK105 in the treatment of third- and above -line advanced pancreatic cancer patients, in order to find a better therapy strategy for pancreatic cancer patients.
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Treatment group | Experimental | Anlotinib plus AK105 |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Anlotinib plus AK105 | Drug | Anlotinib： a multi-kinase inhibitor AK105： an anti-PD-1 antibody |
|
| Measure | Description | Time Frame |
|---|---|---|
| Disease control rate (DCR) based on RECIST v. 1 1 | Disease control rate (DCR) based on RECIST v. 1 1 by investigators | 6 weeks |
| Measure | Description | Time Frame |
|---|---|---|
| Objective response rate (ORR) based on RECIST V. 1.1 | Objective response rate (ORR) based on RECIST V. 1.1 by investigators | 6 weeks |
| Progression free survival (PFS) measured from the date of anlotinib plus AK105 initiation to the time of progression |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| XIANG WANG, Master | Contact | 86-1069158773 | wangxiang5123@126.com |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Department of Medical Oncology, Peking Union Medical College Hospital, Chinese Academy of Medical Sciences | Recruiting | Beijing | Beijing Municipality | 100032 | China |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| ID | Term |
|---|---|
| C000625192 | anlotinib |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Progression free survival (PFS) measured from the date of anlotinib plus AK105 initiation to the time of progression by investigators assessment
| 6 weeks |
| Overall survival (OS) measured from the date of anlotinib plus AK105 initiation to the time of death of any cause | Overall survival (OS) measured from the date of anlotinib plus AK105 initiation to the time of death of any cause by investigators assessment | 6 weeks |
| Number of participants with treatment-related adverse events as assessed by CTCAE v4.0 | adverse events assessed using the National Cancer Institute Common Terminology Criteria for Adverse Events (version 4.0). | 6 weeks |